1-6 of 6
Marilina Amabile, BD
Close
Sort by
Journal Articles

A Prospective Study of Imatinib 400 mg vs 800 mg Frontline in High Risk Ph+ Chronic Myeloid Leukemia (CML) Patients.

Michele Baccarani, MD, Fausto Castagnetti, MD, Kimmo Porkka, MD, Johan L. Nielsen, MD, Henrik Hjorth-Hansen, MD, Ibrahim Haznedaroglu, MD, Arnon Nagler, MD, Giovanna Rege-Cambrin, MD, Giorgina Specchia, MD, Marilina Amabile, BD, Nicoletta Testoni, BD, Francesca Palandri, MD, Fabrizio Pane, MD, Giuliana Alimena, MD, Giovanni Martinelli, MD, Gianantonio Rosti, MD, Bengt Simonsson, MD
Journal: Blood
Blood (2007) 110 (11): 26.
https://doi.org/10.1182/blood.V110.11.26.26
Published: 2007
Journal Articles

Imatinib High Dose (800 mg): Results of a Phase II Trial of the GIMEMA (Gruppo Italiano Malattie Ematologiche Dell’Adulto) CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.

Gianantonio Rosti, MD, Fausto Castagnetti, MD, Marilina Amabile, BD, Nicoletta Testoni, BD, Angela Poerio, BD, Giulia Marzocchi, BD, Massimo Breccia, MD, Francesca Palandri, MD, Tamara Intermesoli, MD, Fabio Stagno, MD, Giorgina Specchia, MD, Elisabetta Abruzzese, MD, Panagiota Giannoulia, MD, Giuseppe Saglio, MD, Fabrizio Pane, MD, Francesca Rancati, BD, Arnon Nagler, MD, Ibrahim Haznedaroglu, MD, Kimmo PorkKa, MD, Henrik Hjorth-Hansen, MD, Johan L. Nielsen, MD, Bengt Simonsson, MD, Giovanni Martinelli, MD, Michele Baccarani, MD
Journal: Blood
Blood (2006) 108 (11): 4776.
https://doi.org/10.1182/blood.V108.11.4776.4776
Published: 2006
Journal Articles

Imatinib 400 mg in Early Chronic Phase CML: Results of a Multicentric, Prospective Non Academical Observational Study (by the GIMEMA CML Working Party).

Gianantonio Rosti, MD, Fausto Castagnetti, MD, Ilaria Iacobucci, BD, Marilina Amabile, BD, Francesca Palandri, MD, Panagiota Giannoulia, MD, Giuliana Alimena, MD, Nicoletta Testoni, BD, Simona Luatti, BD, Bruno Martino, MD, Giorgina Specchia, MD, Serena Rupoli, MD, Adele Capucci, MD, F. Cavazzini, MD, Franca Radaelli, MD, Ester Orlandi, MD, Giovanna Rege Cambrin, MD, Emilio Usala, MD, Nicoletta Testoni, MD, Fabrizio Pane, MD, Giuseppe Saglio, MD, Giovanni Martinelli, MD, Michele Baccarani, MD
Journal: Blood
Blood (2006) 108 (11): 4777.
https://doi.org/10.1182/blood.V108.11.4777.4777
Published: 2006
Journal Articles

Deletions of the Derivative Chromosome 9 Do Not Influence Response to Imatinib of Early Chronic Phase Chronic Myeloid Leukemia Patients (A GIMEMA Working Party Analysis).

Fausto Castagnetti, MD, Giulia Marzocchi, BD, Simona Luatti, BD, Francesca Buontempo, BD, Carmen Baldazzi, BD, Francesca Palandri, MD, Panagiota Giannoulia, MD, Marilina Amabile, BD, Ilaria Iacobucci, BD, Marco Mancini, MD, Ursula Giussani, MD, Giorgina Specchia, MD, Antonio Cuneo, MD, Emilia Gugliano, MD, Simonetta Kerim, MD, Bruno Modaferri, MD, Elisabetta Abruzzese, MD, Giovanni Martinelli, MD, Nicoletta Testoni, BD, Gianantonio Rosti, MD, Michele Baccarani, MD
Journal: Blood
Blood (2006) 108 (11): 2112.
https://doi.org/10.1182/blood.V108.11.2112.2112
Published: 2006
Journal Articles

Imatinib 800 mg: Preliminary Results of a Phase II Trial of the GIMEMA CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.

Gianantonio Rosti, MD, Giovanni Martinelli, MD, Fausto Castagnetti, MD, Nicoletta Testoni, BD, Giorgina Specchia, MD, Renato Bassan, MD, Fabio Stagno, MD, Massimo Breccia, MD, Elisabetta Abruzzese, MD, Giuseppe Saglio, MD, Fabrizio Pane, MD, Bengt Simonsson, MD, Johan L. Nielsen, MD, Henrik Hjorth-Hansen, MD, Kimmo PorkKa, MD, Ibrahim Haznedaroglu, MD, Arnon Nagler, MD, Marco Vignetti, MD, Domenico Russo, MD, Marilina Amabile, BD, Michele Baccarani, MD
Journal: Blood
Blood (2005) 106 (11): 1098.
https://doi.org/10.1182/blood.V106.11.1098.1098
Published: 2005
Journal Articles

Imatinib in the Treatment of CML Patients ≥ 65 Years Old in Late Chronic Phase: Results of a Phase II Study of the GIMEMA CML Working Party.

Simona Bassi, MD, Fausto Castagnetti, MD, Marilina Amabile, BD, Barbara Giannini, BD, Daniela Cilloni, MD, Barbara Izzo, BD, Antonio De Vivo, MD, Simona Luatti, BD, Nicoletta Testoni, BD, Giovanna Rege-Cambrin, MD, Ilaria Iacobucci, BD, Enrico Gottardi, BD, Fabrizio Pane, MD, Francesco Salvatore, MD, Alessandra Dorigo, MD, Giuseppe Saglio, MD, Giovanni Martinelli, MD, Gianantonio Rosti, MD, Michele Baccarani, MD
Journal: Blood
Blood (2004) 104 (11): 2935.
https://doi.org/10.1182/blood.V104.11.2935.2935
Published: 2004